UA91493C2 - Стабілізовані рідкі композиції інтерферону у фармацевтичних контейнерах - Google Patents
Стабілізовані рідкі композиції інтерферону у фармацевтичних контейнерахInfo
- Publication number
- UA91493C2 UA91493C2 UAA200510442A UAA200510442A UA91493C2 UA 91493 C2 UA91493 C2 UA 91493C2 UA A200510442 A UAA200510442 A UA A200510442A UA A200510442 A UAA200510442 A UA A200510442A UA 91493 C2 UA91493 C2 UA 91493C2
- Authority
- UA
- Ukraine
- Prior art keywords
- protein formulations
- pharmaceutical containers
- coated pharmaceutical
- stabilized protein
- liquid stabilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/002—Closures to be pierced by an extracting-device for the contents and fixed on the container by separate retaining means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/005—Closures provided with linings or internal coatings so as to avoid contact of the closure with the contents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Mechanical Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Винахід належить до медицини та стосується контейнера для рідкої фармацевтичної композиції, яка містить інтерферон. Контейнер являє собою флакон, ампулу, пляшку малої місткості або тубу та включає закупорювальний засіб, вкритий покриттям з інертного фторованого матеріалу, зокрема політетрафторетилену, причому внутрішня поверхня контейнера вкрита покриттям з інертного матеріалу, зокрема силікону.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03010671 | 2003-05-13 | ||
PCT/EP2004/050779 WO2004100979A2 (en) | 2003-05-13 | 2004-05-12 | Liquid stabilized protein formulations in coated pharmaceutical containers |
Publications (1)
Publication Number | Publication Date |
---|---|
UA91493C2 true UA91493C2 (uk) | 2010-08-10 |
Family
ID=33442722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200510442A UA91493C2 (uk) | 2003-05-13 | 2004-05-12 | Стабілізовані рідкі композиції інтерферону у фармацевтичних контейнерах |
Country Status (23)
Country | Link |
---|---|
US (2) | US7540382B2 (uk) |
EP (2) | EP1633388B1 (uk) |
JP (2) | JP2007502684A (uk) |
KR (1) | KR101084412B1 (uk) |
CN (1) | CN1809376B (uk) |
AR (1) | AR044302A1 (uk) |
AU (1) | AU2004237982C1 (uk) |
BR (1) | BRPI0410679A (uk) |
CA (1) | CA2523477A1 (uk) |
CY (1) | CY1115233T1 (uk) |
DK (1) | DK1633388T3 (uk) |
EA (1) | EA008308B1 (uk) |
ES (1) | ES2471942T3 (uk) |
HK (1) | HK1088558A1 (uk) |
HR (1) | HRP20140267T1 (uk) |
IL (1) | IL171912A (uk) |
MX (1) | MXPA05012191A (uk) |
NO (1) | NO20055774L (uk) |
PL (1) | PL1633388T3 (uk) |
PT (1) | PT1633388E (uk) |
SI (1) | SI1633388T1 (uk) |
UA (1) | UA91493C2 (uk) |
WO (1) | WO2004100979A2 (uk) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200609412B (en) * | 2004-05-17 | 2008-07-30 | Ares Trading Sa | Hydrogel interferon formulations |
US7731948B2 (en) * | 2004-06-01 | 2010-06-08 | Ares Trading S.A. | Stabilized interferon liquid formulations |
CN101102739B (zh) * | 2005-01-12 | 2017-02-08 | 比奥根Ma公司 | 运输干扰素‑β的方法 |
WO2007016562A2 (en) * | 2005-07-29 | 2007-02-08 | Amgen Inc. | Formulations that inhibit protein aggregation |
US20070253985A1 (en) * | 2006-04-26 | 2007-11-01 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
KR100785070B1 (ko) | 2006-07-11 | 2007-12-12 | 삼성전자주식회사 | 휴대 단말기에서 디지털 저작권 관리 콘텐츠 재생 방법 및장치 |
EP2170268A2 (en) | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
EP2234645B1 (en) * | 2007-12-20 | 2012-05-02 | Merck Serono S.A. | Peg-interferon-beta formulations |
BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
RU2609658C2 (ru) | 2009-12-21 | 2017-02-02 | Дженентек, Инк. | Состав, содержащий антитело |
US8802603B2 (en) | 2010-06-17 | 2014-08-12 | Becton, Dickinson And Company | Medical components having coated surfaces exhibiting low friction and low reactivity |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
FR2966044B1 (fr) * | 2010-10-18 | 2012-11-02 | Sanofi Pasteur | Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
CA2890933C (en) | 2012-12-03 | 2021-06-08 | Novobiotic Pharmaceuticals, Llc | Novel depsipeptide and uses thereof |
WO2014159554A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
BR112015017307A2 (pt) | 2013-03-14 | 2017-11-21 | Abbvie Inc | composições de espécies com baixa acidez e métodos para produção e uso das mesmas |
ES2837626T3 (es) | 2013-07-10 | 2021-07-01 | Matrix Biology Inst | Composiciones de hialuronano con alta elasticidad y usos de las mismas |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
BR112016010475B1 (pt) * | 2014-03-13 | 2021-07-20 | Stevanato Group International A.S. | Método de manuseio de uma formulação farmacêutica líquida |
US20170226552A1 (en) | 2014-07-03 | 2017-08-10 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt |
WO2016007764A1 (en) | 2014-07-09 | 2016-01-14 | Abbvie Inc. | Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars |
WO2016144773A1 (en) | 2015-03-06 | 2016-09-15 | Abbvie Inc. | Arabinosylated glycoproteins |
WO2016163764A2 (ko) * | 2015-04-07 | 2016-10-13 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
RU2727809C2 (ru) | 2015-09-24 | 2020-07-24 | Матрикс Байолэджи Инститьют | Композиции гиалуроновой кислоты с высокоэластичными свойствами и способы их применения |
WO2017147003A1 (en) | 2016-02-26 | 2017-08-31 | Novobiotic Pharmaceuticals, Llc | Novel macrocyclic antibiotics and uses thereof |
FI126979B (en) | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and use thereof |
CA3057987A1 (en) | 2017-04-04 | 2018-10-11 | Novobiotic Pharmaceuticals, Llc | Novel depsipeptides and uses thereof |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2622598A (en) | 1951-03-08 | 1952-12-23 | Premo Pharmaceutical Lab Inc | Drain-clear container for aqueous liquid pharmaceutical preparations |
US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
JP3332379B2 (ja) * | 1992-05-06 | 2002-10-07 | マリンクロッド・インコーポレイテッド | 次亜塩素酸ナトリウム溶液の安定性保持用容器封鎖物システム |
US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
TW249202B (uk) * | 1993-08-13 | 1995-06-11 | Ciba Gerigy Corp | |
TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
WO1997017087A1 (en) * | 1995-11-07 | 1997-05-15 | Genentech, Inc. | Stabilizing formulation for ngf |
US6142977A (en) | 1996-10-18 | 2000-11-07 | Schering Ag | Prefilled, sterilized syringe with a new and improved plug |
CA2275890C (en) * | 1996-12-24 | 2011-11-01 | Biogen, Inc. | Stable liquid interferon formulations |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
CN2326243Y (zh) * | 1997-09-29 | 1999-06-30 | 程继勇 | 覆膜药用瓶塞 |
US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
CN2441750Y (zh) * | 2000-06-23 | 2001-08-08 | 程继勇 | 表面覆膜药用橡胶瓶塞 |
JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
CN1133565C (zh) * | 2001-10-18 | 2004-01-07 | 郑秀娣 | 药品瓶塞隔离膜 |
-
2004
- 2004-05-11 AR ARP040101607 patent/AR044302A1/es not_active Application Discontinuation
- 2004-05-12 PT PT04760770T patent/PT1633388E/pt unknown
- 2004-05-12 EP EP04760770.0A patent/EP1633388B1/en not_active Expired - Lifetime
- 2004-05-12 BR BRPI0410679 patent/BRPI0410679A/pt not_active IP Right Cessation
- 2004-05-12 ES ES04760770.0T patent/ES2471942T3/es not_active Expired - Lifetime
- 2004-05-12 CN CN2004800169917A patent/CN1809376B/zh not_active Expired - Lifetime
- 2004-05-12 UA UAA200510442A patent/UA91493C2/uk unknown
- 2004-05-12 JP JP2006530185A patent/JP2007502684A/ja not_active Withdrawn
- 2004-05-12 MX MXPA05012191A patent/MXPA05012191A/es active IP Right Grant
- 2004-05-12 WO PCT/EP2004/050779 patent/WO2004100979A2/en active Application Filing
- 2004-05-12 CA CA 2523477 patent/CA2523477A1/en not_active Withdrawn
- 2004-05-12 DK DK04760770T patent/DK1633388T3/da active
- 2004-05-12 EP EP20110152658 patent/EP2324845A1/en not_active Withdrawn
- 2004-05-12 EA EA200501692A patent/EA008308B1/ru not_active IP Right Cessation
- 2004-05-12 PL PL04760770T patent/PL1633388T3/pl unknown
- 2004-05-12 KR KR20057021160A patent/KR101084412B1/ko not_active IP Right Cessation
- 2004-05-12 US US10/556,467 patent/US7540382B2/en not_active Ceased
- 2004-05-12 US US13/151,459 patent/USRE43331E1/en active Active
- 2004-05-12 AU AU2004237982A patent/AU2004237982C1/en not_active Expired
- 2004-05-12 SI SI200432149T patent/SI1633388T1/sl unknown
-
2005
- 2005-11-13 IL IL17191205A patent/IL171912A/en active IP Right Grant
- 2005-12-06 NO NO20055774A patent/NO20055774L/no not_active Application Discontinuation
-
2006
- 2006-09-21 HK HK06110556A patent/HK1088558A1/xx not_active IP Right Cessation
-
2012
- 2012-01-13 JP JP2012005485A patent/JP2012096063A/ja active Pending
-
2014
- 2014-03-20 HR HRP20140267TT patent/HRP20140267T1/hr unknown
- 2014-05-30 CY CY20141100386T patent/CY1115233T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA91493C2 (uk) | Стабілізовані рідкі композиції інтерферону у фармацевтичних контейнерах | |
IL172835A0 (en) | A composition for stabilizing active protein ingredients in pharmaceutical composition containing at least 2 amino acids | |
ES2569949T3 (es) | Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina | |
CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
AR092919A2 (es) | Composicion farmaceutica liquida | |
ES2164098T3 (es) | Composiciones farmaceuticas que contienen una proteina bactericida aumentadora de la permeabilidad y un tensioactivo. | |
HK1000903A1 (en) | Stabilized pharmaceutical peptide compositions | |
WO2003007868A8 (en) | Storage of liquid compositions | |
MXPA05008138A (es) | Composiciones orales de fenretinida que tienen biodisponibilidad incrementada y metodos de uso de las mismas. | |
PL362797A1 (en) | Medical aerosol formulations | |
HK1083200A1 (en) | Pharmaceutical preparations for oral administration, containing ion- exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents | |
AR040527A1 (es) | Formulaciones de hgh en alta concentracion que contienen glicina | |
BRPI0410488A (pt) | composição farmacêutica lìquida estabilizada livre de hsa, método para preparação de composição farmacêutica lìquida estabilizada livre de hsa, recipiente vedado hermeticamente e kit para administração de múltiplas doses de composição farmacêutica lìquida estabilizada livre de hsa' | |
WO2008070721A3 (en) | High protein concentration formulations containing mannitol | |
DE69912262D1 (de) | Retinolhaltiges arzneimittel kompatibel mit weichgelatinekapseln | |
MX2021014332A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-angptl3. | |
CN1396828A (zh) | 含有培美西德以及一硫代甘油l-半胱氨酸或巯乙酸的药物组合物 | |
HK1041416A1 (en) | Compositions and methods for preserving platelets. | |
AR037131A1 (es) | Formulaciones de jarabe de ribavirina | |
JP2001309986A (ja) | 塗布容器入り皮膚外用剤組成物 | |
AU2003296602A1 (en) | Quaternary compounds comprising propolis as the active substance | |
AU2003224107A1 (en) | Soluble composition containing sporopollenin and the use thereof | |
ITMI20020194A1 (it) | Contentitore per prodotti pastosi e cremosi in genere quali prodotti cosmetici farmaceutici e simili | |
GEP20053581B (en) | Pharmaceutical Composition and Method for Preparation Thereof | |
AU2624499A (en) | Oral compositions at low dosage of cytotoxic proteins |